Publications by authors named "Nadezhda Kovalenko"

Claim this Profile
C
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina Orlova, Vladimir Moiseenko, Nadezhda Kovalenko

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina Orlova, Vladimir Moiseenko, Nadezhda Kovalenko

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT).
Lev Demidov, Galina Kharkevich, Natalia Petenko, Vladimir Moiseenko, Svetlana Protsenko, Nadezhda Kovalenko

Front Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance of winter wheat varieties to tan spot in the North Caucasus region of Russia.
Oksana Yu Kremneva, Nina V Mironenko, Galina V Volkova, Olga A Baranova, Yuri S Kim, Nadezhda M Kovalenko

Saudi J Biol Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Douglas W Blayney, Qingyuan Zhang, Jifeng Feng, Yanqiu Zhao, Igor Bondarenko, Nadezhda Kovalenko

JAMA Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Martin Reck, Alexander Luft, Igor Bondarenko, Serhii Shevnia, Dmytro Trukhin, Nadezhda V Kovalenko

Lung Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
species mediated synthesis of silver nanoparticles and their antibacterial activity against opportunistic pathogens .
Inna Garmasheva, Nadezhda Kovalenko, Sergey Voychuk, Andriy Ostapchuk, Olena Livins'ka

Bioimpacts· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, Nadezhda Kovalenko

Lancet· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, Nadezhda Kovalenko

N Engl J Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Antonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, Daniel Stroyakovsky, Martin Gore, Nadezhda Kovalenko

Eur J Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis